MK-677 (Ibutamoren) Research Summary: Human Evidence, Limits, and Safety

MK-677 (ibutamoren) is an investigational, orally active growth hormone secretagogue. It is often listed beside SARMs, but it is not a selective androgen receptor modulator. MK-677 acts as an agonist at the ghrelin/growth hormone secretagogue receptor (GHS-R1a), increasing endogenous growth hormone (GH) pulses and downstream insulin-like growth factor 1 (IGF-1).

Human studies show consistent target engagement – GH and IGF-1 rise – but clinical outcomes are mixed. Some trials reported changes in fat-free mass, nitrogen balance, sleep architecture, or bone-turnover markers. Other studies found no improvement in strength, physical function, Alzheimer disease progression, or bone density at most measured sites. MK-677 is not authorized by Health Canada for therapeutic use.

MK-677 research: key points

Compound class: nonpeptide ghrelin-receptor agonist and growth hormone secretagogue; not a SARM.
Most consistent finding: increased pulsatile GH secretion and serum IGF-1 in controlled studies.
Body-composition finding: a 12-month study in 65 adults aged 60-81 reported increased fat-free mass, but no corresponding improvement in strength or function.
Metabolic signal: fasting glucose increased and insulin sensitivity decreased in the same older-adult study.
Commonly reported adverse effects: increased appetite, transient edema, and muscle pain; enhanced GH signalling also raises broader safety questions.
Serious safety signal: an older hip-fracture population had an early-stopped trial; see the primary report and the population limits discussed below.
Regulatory status: investigational and not an authorized medicine or natural health product in Canada.

How MK-677 works

MK-677 mimics part of ghrelin’s signalling by activating GHS-R1a. This stimulates the pituitary GH axis while preserving a pulsatile pattern of secretion. GH then promotes hepatic and peripheral production of IGF-1. Because the compound acts upstream of GH rather than replacing GH directly, studies have focused on endocrine response, body composition, sleep, recovery from catabolic states, bone turnover, and age-related functional decline.

Target engagement is not the same as clinical benefit. A rise in GH or IGF-1 confirms biological activity, but whether that change improves a meaningful outcome depends on the population, duration, endpoint, and adverse-effect profile.

Human evidence by research question

GH, IGF-1, and body composition in older adults

The best-known trial enrolled 65 healthy adults aged 60 to 81 in a two-year, double-blind, randomized, placebo-controlled modified-crossover study. After one year, mean fat-free mass changed by +1.1 kg in the MK-677 group compared with -0.5 kg in the placebo group. GH and IGF-1 rose toward levels observed in younger adults.

The same trial also found important limits. Increased fat-free mass did not produce significant improvements in strength, function, or quality of life. Mean body weight increased more with MK-677, fasting glucose rose by about 0.3 mmol/L (5 mg/dL), and insulin sensitivity decreased. Increased appetite, mild lower-extremity edema, and muscle pain were among the most frequent reported effects.

Sleep architecture

Copinschi and colleagues (1997) studied eight younger adults in a randomized, placebo-controlled crossover experiment and six older adults in a separate protocol that compared sleep measurements with baseline. The younger-adult experiment reported longer stage IV and REM sleep under one treatment condition. The older group showed longer REM sleep and shorter REM latency.

These were brief investigations of sleep architecture, with very small samples and different study designs. They do not establish that MK-677 treats insomnia, improves daytime function, or is safe for long-term sleep use.

Caloric restriction and nitrogen balance

In a randomized crossover experiment involving eight healthy adults undergoing short-term caloric restriction, MK-677 shifted mean daily nitrogen balance from negative under placebo to slightly positive during the treatment week. The study supports a physiological effect on protein metabolism under tightly controlled conditions, but its sample size and two-week periods do not establish long-term body-composition or functional benefit.

Bone turnover and bone mineral density

A randomized study of 292 postmenopausal women with low femoral-neck bone mineral density compared MK-677, alendronate, the combination, and placebo. MK-677 increased IGF-1 and markers of both bone formation and resorption. The combination produced a larger femoral-neck BMD increase than alendronate alone, but a similar enhancement was not found at the lumbar spine, total hip, or total body. The authors cautioned that the limited BMD benefit had to be weighed against effects associated with enhanced GH secretion.

Bone-turnover markers should therefore not be presented as proof of broadly improved bone health or fracture prevention.

Alzheimer disease: target engagement without clinical benefit

A 12-month randomized trial in 563 people with mild to moderate Alzheimer disease found that MK-677 increased serum IGF-1, but it did not slow clinical progression. There were no significant treatment differences on the study’s cognitive, global, or activities-of-daily-living outcomes. This is a useful example of why a biological response should not be confused with a demonstrated therapeutic result.

Hip-fracture recovery: an early-stopped trial

A randomized trial reported by Adunsky and colleagues (2011) enrolled 123 older patients recovering from hip fracture. IGF-1 increased, but most functional measures did not improve. The trial ended early after a congestive heart failure safety signal.

This finding concerns a specific older patient population. It does not provide a reliable risk estimate for other groups, and it should not be omitted when discussing MK-677 safety. Evidence from this trial cannot establish safety for healthy people or unsupervised exposure.

Evidence summary table

Scroll horizontally to view all columns.

Study	Population and design	Main finding	Important limitation
Nass et al., 2008	65 healthy adults aged 60-81; randomized controlled modified-crossover trial	Higher GH/IGF-1 and fat-free mass	No significant strength or functional improvement; glucose and insulin-sensitivity changes
Copinschi et al., 1997	8 younger adults: placebo-controlled crossover; 6 older adults: separate baseline-comparison protocol	Changes in stage IV and REM sleep	Very small samples, brief follow-up and different designs
Murphy et al., 2001	292 postmenopausal women with low femoral-neck BMD	Higher IGF-1 and bone-turnover markers; limited site-specific BMD signal	No broad BMD improvement across measured sites
Sevigny et al., 2008	563 people with mild-moderate Alzheimer disease; 12-month randomized trial	IGF-1 increased	No slowing of clinical progression
Murphy et al., 1998	8 adults under short-term caloric restriction; randomized crossover	Improved nitrogen balance during the study period	Short experiment; no demonstration of lasting functional benefit
Adunsky et al., 2011	123 older hip-fracture patients; randomized trial	Higher IGF-1 without improvement in most functional measures	Stopped early following a heart-failure safety signal

Safety signals and unresolved questions

Controlled studies have reported increased appetite, fluid retention or edema, muscle discomfort, increased body weight, higher fasting glucose, reduced insulin sensitivity, and changes in cortisol. The significance of these effects depends on the study population and duration. The available trials do not establish long-term safety for healthy users, compounded products, or unsupervised exposure.

Additional uncertainty comes from product quality. An online product labelled “MK-677” may not contain the stated ingredient or concentration. Health Canada warns that unauthorized bodybuilding products can contain hidden or different drugs and have not been reviewed for safety, efficacy, or quality.

For a practical assessment framework, use the guide to COAs, identity, purity, concentration, and material-lot documentation.

Legal and regulatory status in Canada

Health Canada lists ibutamoren (MK-677) among drugs that may be presented as SARMs in bodybuilding products, while clarifying that it is not itself a SARM. MK-677 is not authorized in Canada as a therapeutic product or natural health product. It should not be marketed as a supplement or represented as approved for treating disease, changing body composition, improving sleep, or enhancing performance.

An authorized Canadian prescription drug carries an eight-digit Drug Identification Number (DIN). Health Canada’s Drug Product Database can be used to confirm authorization status. A research label is not a substitute for regulatory authorization or evidence of safety for human use.

How to evaluate an MK-677 research claim

Confirm the compound class: MK-677 is a ghrelin-receptor agonist, not an androgen-receptor modulator.
Separate endocrine changes from outcomes: higher GH or IGF-1 does not automatically mean stronger muscles, better cognition, or improved bone health.
Check sample size and population: many studies were small or enrolled older adults with specific clinical characteristics.
Report null results: lack of functional or cognitive benefit is part of the evidence.
Include metabolic and fluid-retention signals: a balanced summary should not discuss only lean mass or sleep measures.

Related research resources

References

How this evidence summary was checked

Source check: September 6, 2026. This is a narrative overview of selected human studies. Citation details and selected outcome statements were checked against PubMed records, with accessible primary full text consulted where needed. Targeted searches for ibutamoren, MK-677 and hip-fracture research were used to check for missing safety evidence.

This was not a systematic review or meta-analysis, and it does not claim to include every study. Findings should be interpreted within each study’s population, design, duration and measured outcomes. This page is published by Canada SARMs, a commercial research-compound supplier, and is not an independent product evaluation. It does not provide medical or legal advice or recommend human use.